A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2006
11/21/2006	US7138371 Remodeling and glycoconjugation of peptides
11/21/2006	US7138274 Advanced oral poliovirus vaccine (Adv-OPV) deprived of the possibility of vaccine associated paralytic poliomyelities (VAPP)
11/21/2006	US7138252 For prevention/treatment of allergies/cancer/drug addiction/poisoning
11/21/2006	US7138247 An antibody directed against particular amino acid regions of Hsp70B' and its preparation by administering a peptide corresponding, or antigenically equivalent, to those regions; detection of the stress-inducible Hsp70B' protein
11/21/2006	US7138244 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
11/21/2006	US7138243 NTB-A, a surface molecule involved in natural killer cells activity
11/21/2006	US7138237 Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
11/21/2006	US7138234 Gene involved in CADASIL, method of diagnosis and therapeutic application
11/21/2006	US7138144 Restricting outflow of fluid from a portion of the circulatory system; administering a dose of bone marrow cells derived from donor to a body part delimiting portion of circulatory system, prior to, concomitantly with or following transplantation
11/21/2006	US7138127 Clostridial toxin derivatives and methods for treating pain
11/21/2006	US7138126 Modifying wild strain of enteroinvasive Shigella; cannot spread within infected cells and from infected to uninfected cells of the host; vaccines; deactivation by inserting transposon into gene; mutagenizing; genetically engineered by allelic exchange
11/21/2006	US7138125 Polypeptide for prevention, therapy of bacteria infections; gramnegative bacteria; therapy for reduced lactation in animals
11/21/2006	US7138124 Lipopolysaccharides; forming antibodies; isolation exterior membrane polypeptide
11/21/2006	US7138123 Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
11/21/2006	US7138121 Biosensors utilizing dendrimer-immobilized ligands and there use thereof
11/21/2006	US7138120 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
11/21/2006	US7138119 Compositions and methods for inhibition of HIV-1 infection
11/21/2006	US7138118 Methods of treating rheumatoid arthritis with anti-TNF antibodies
11/21/2006	US7138117 Antigen-binding fragment or antibody which binds to a mammalian CC-chemokine receptor 4 (CCR4); medical diagosis, therapy, or prophylaxis; antiinflammatory agents
11/21/2006	US7138116 Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
11/21/2006	US7138115 Administering monoclonal or polyclonal antibody to treat multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes melitis and autoimmune inflammatory eye disease
11/21/2006	US7138112 Plasmid maintenance system for antigen delivery
11/21/2006	US7138103 Completitive binding
11/21/2006	CA2478621C Botulinum toxin pharmaceutical compositions
11/21/2006	CA2433386C Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r9
11/21/2006	CA2253736C Antimicrobial treatment for herpes simplex virus and other infectious diseases
11/21/2006	CA2154063C Treatment of h. pylori associated gastroduodenal disease
11/21/2006	CA2078003C Tumor killing effects of enterotoxins and related compounds
11/17/2006	CA2549902A1 Cd44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
11/16/2006	WO2006122257A2 Nebulization of monoclonal antibodies for treating pulmonary diseases
11/16/2006	WO2006122222A2 Shape tunable plasmonic nanoparticles
11/16/2006	WO2006122047A1 Cardiovascular disease therapies
11/16/2006	WO2006122046A2 Vascular disease therapies
11/16/2006	WO2006121895A2 Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
11/16/2006	WO2006121871A2 Compositions and methods for modulating cells via cd14 and toll-like receptor 4 signaling pathway
11/16/2006	WO2006121869A2 Compositions and methods for treating mood and anxiety disorders
11/16/2006	WO2006121852A2 Anti-cd19 antibody therapy for autoimmune disease
11/16/2006	WO2006121810A2 Trimeric ox40-immunoglobulin fusion protein and methods of use
11/16/2006	WO2006121664A2 Polypeptides for inducing a protective immune response against staphylococcus aureus
11/16/2006	WO2006121656A2 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
11/16/2006	WO2006121633A2 Activation of the dax-1 and shp nuclear orphan receptors
11/16/2006	WO2006121579A2 Targeted gene addition in stem cells
11/16/2006	WO2006121558A2 Method of prevention and treatment of aging, a related disorders and/or age-related manifestations includi r c erosis.
11/16/2006	WO2006121428A1 Use of nk cell inhibition to facilitate persistence of engrafted mhc- i negative cells
11/16/2006	WO2006121422A2 Antibodies against clostridium difficile toxins and uses thereof
11/16/2006	WO2006121159A1 Humanized cdr-grafted antibody specifically reacting with cd10 and antibody fragment of the same
11/16/2006	WO2006120576A2 Immunogens for meningitidis-a vaccines
11/16/2006	WO2006120575A2 Tcr-independent activation of t cells with co-lignation of cd28 and cd81
11/16/2006	WO2006120503A1 Pharmaceutical composition for treating acquired immunodeficiency
11/16/2006	WO2006120473A2 Mhc class i and ii peptide antigens derived from tumour antigen 5t4
11/16/2006	WO2006120034A1 Vaccine composition
11/16/2006	WO2006119983A2 Genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
11/16/2006	WO2006119965A2 Growth factor mutants with altered biological attributes
11/16/2006	WO2006119560A1 Immunoglobulin fraction and process therefor
11/16/2006	WO2006119527A2 Melanoma-associated endogenous retrovirus (merv) derived peptide sequences and their therapeutic/ diagnostic use
11/16/2006	WO2006104677A3 Antibodies that bind ov064 and methods of use therefor
11/16/2006	WO2006091332A3 Intranasal administration of active agents to the central nervous system
11/16/2006	WO2006084078A3 Jam-3 and antibodies that bind thereto
11/16/2006	WO2006072624A3 Compositions and methods for treating viral infection
11/16/2006	WO2006068663A3 Vaccine compositions for treating coronavirus infection
11/16/2006	WO2006062917A3 Alpha thymosin peptides as cancer vaccine adjuvants
11/16/2006	WO2006061253A3 Combination of tyrosine kinase inhibitor and her-2/neu for cancer therapy
11/16/2006	WO2006050219A3 Broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
11/16/2006	WO2006031370A3 Polypeptide variants with altered effector function
11/16/2006	WO2006029183A3 Compositions and methods for the diagnosis and treatment of tumor
11/16/2006	WO2006005706A8 Combination therapy for preventing or treating alzheimer's disease, and kit therefor
11/16/2006	WO2005023981A3 Libraries of chimeric cellulose binding proteins and methods of use thereof
11/16/2006	WO2004108157A8 Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
11/16/2006	WO2004058157A3 Yeast-based vaccines as immunotherapy
11/16/2006	WO2003087129A3 Immunogenic peptides, and method of identifying same
11/16/2006	WO2003073916A8 Immune regulation
11/16/2006	US20060259996 Structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like (tissue differentiation factor) receptors; methods of detecting, preventing, and treating TDF-associated disorders
11/16/2006	US20060258860 Such as N-(2-ethoxybenzyl)-5-hydroxy-1-methyl-2-(4-methylphenyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; for preventing, treating or delaying AIDS
11/16/2006	US20060258849 Nucleic acids and proteins from streptococcus groups A & B
11/16/2006	US20060258848 Human antipneumococcal antibodies from non-human animals
11/16/2006	US20060258842 Fully humanized monoclonal antibodies that neutralize Bacillus anthracis lethal toxin; vaccines
11/16/2006	US20060258841 Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
11/16/2006	US20060258611 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference
11/16/2006	US20060258605 Nucleolin-mediated cancer diagnostics and therapy
11/16/2006	US20060258594 Antibodies to the HIV-1 Tat protein, which bind specifically to a specific epitope found in different HIV-1 strains and subtypes; for use in passive therapy
11/16/2006	US20060258564 Method for synthesizing conformationally constrained peptides, peptidomimetics and the use thereof as synthetic vaccines
11/16/2006	US20060257989 Truncated aggrecanase molecules
11/16/2006	US20060257981 culturing a microorganism belonging to the species Dactylosporangium, in a nutrient medium and isolating tiacumicin B; antibiotics used for prophylaxis and therapy of bacterial infections
11/16/2006	US20060257974 Vaccinia virus vector comprising a nucleic acid encoding a fusion protein amino acid sequence consisting of Vif, Vpr, Vpu, Vpx, Rev, Tat, and Nef; genetic vaccines for treating viral diseases
11/16/2006	US20060257940 Transformed Shigella
11/16/2006	US20060257928 ANGE gene in atopy
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257852 Severe acute respiratory syndrome coronavirus
11/16/2006	US20060257850 Methods of treatment and diagnosis of patients with hepatitis c infection
11/16/2006	US20060257466 Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis
11/16/2006	US20060257431 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells
11/16/2006	US20060257430 Methods of modulating intracellular degradation rates of toxins
11/16/2006	US20060257429 Vaccine for periodontal disease
11/16/2006	US20060257428 Assays and therapies for latent viral infection
11/16/2006	US20060257427 Molecule (antibody, peptide or chemical), coupled to a detectable label, cytotoxic agent or solid support, that specifically binds an extracellular portion of the latent viral membrane bound protein of Epstein-Barr Virus expressed in the latent viral membrane in the latent life cycle
11/16/2006	US20060257426 Emulsion comprising an aqueous phase, an oil phase, and a solvent and an immunogen
11/16/2006	US20060257425 Inactivated nodavirus vaccine
11/16/2006	US20060257424 Having mutation in viral nucleic acid encoding viral protein 2; bird and chicken vaccines
11/16/2006	US20060257423 Hepatitis B vaccine (HeVac) and Bacille Calmette-Guerin (BCG); cryoprotectants; lyophilization; heat stability; tuberculosis
11/16/2006	US20060257421 Pneumolysin derivatives

1 ... 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 ... 1823